These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1121 related articles for article (PubMed ID: 17314516)

  • 1. GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment.
    Xu L; Hynes RO
    Cell Cycle; 2007 Jan; 6(2):160-5. PubMed ID: 17314516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2.
    Yang L; Friedland S; Corson N; Xu L
    Cancer Res; 2014 Feb; 74(4):1022-31. PubMed ID: 24356421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.
    Xu L; Begum S; Hearn JD; Hynes RO
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9023-8. PubMed ID: 16757564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific and direct modulation of the interaction between adhesion GPCR GPR56/ADGRG1 and tissue transglutaminase 2 using synthetic ligands.
    Salzman GS; Zhang S; Fernandez CG; Araç D; Koide S
    Sci Rep; 2020 Oct; 10(1):16912. PubMed ID: 33037308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
    Herman JF; Mangala LS; Mehta K
    Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion.
    Mangala LS; Arun B; Sahin AA; Mehta K
    Mol Cancer; 2005 Sep; 4():33. PubMed ID: 16153302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Adhesion G-Protein-Coupled Receptor, GPR56/ADGRG1, Inhibits Cell-Extracellular Matrix Signaling to Prevent Metastatic Melanoma Growth.
    Millar MW; Corson N; Xu L
    Front Oncol; 2018; 8():8. PubMed ID: 29450192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR56 in cancer progression: current status and future perspective.
    Yang L; Xu L
    Future Oncol; 2012 Apr; 8(4):431-40. PubMed ID: 22515446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue transglutaminase promotes or suppresses tumors depending on cell context.
    Chhabra A; Verma A; Mehta K
    Anticancer Res; 2009 Jun; 29(6):1909-19. PubMed ID: 19528447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Transglutaminase 2 Activates Epithelial ADAM17: Link to G-Protein-Coupled Receptor 56 (ADGRG1) Signalling.
    Bauer L; Edwards J; Heil A; Dewitt S; Biebermann H; Aeschlimann D; Knäuper V
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular transglutaminase 2 induces myotube hypertrophy through G protein-coupled receptor 56.
    Kitakaze T; Yoshikawa M; Kobayashi Y; Kimura N; Goshima N; Ishikawa T; Ogata Y; Yamashita Y; Ashida H; Harada N; Yamaji R
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118563. PubMed ID: 31666191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR56 interacts with extracellular matrix and regulates cancer progression.
    Xu L
    Adv Exp Med Biol; 2010; 706():98-108. PubMed ID: 21618829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses.
    Stephens P; Grenard P; Aeschlimann P; Langley M; Blain E; Errington R; Kipling D; Thomas D; Aeschlimann D
    J Cell Sci; 2004 Jul; 117(Pt 15):3389-403. PubMed ID: 15199098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of tissue transglutaminase expression in malignant melanoma.
    Fok JY; Ekmekcioglu S; Mehta K
    Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.
    Condello S; Sima L; Ivan C; Cardenas H; Schiltz G; Mishra RK; Matei D
    Cancer Res; 2018 Jun; 78(11):2990-3001. PubMed ID: 29510995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
    Kotsakis P; Wang Z; Collighan RJ; Griffin M
    Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
    Mehta K; Kumar A; Kim HI
    Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
    Mehta K; Fok J; Miller FR; Koul D; Sahin AA
    Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.